Fig. 6From: Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinomaKaplan–Meier analysis of overall survival in small cohort of patients with non-measurable lesions by mRECIST (n = 16). The log-rank test showed significant differences between progressive disease (PD) (n = 8) and stable disease (SD) groups (n = 8) as determined by RECIST 1.1 (P = 0.0312)Back to article page